By Connor Hart
Pfizer said its blood-cancer treatment met the main goal of an ongoing late-stage study, significantly extending the time patients lived without their disease worsening compared with a standard drug combination.
The treatment, Elrexfio, was tested in adults with relapsed or refractory multiple myeloma, an aggressive and currently incurable blood cancer that affects plasma cells made in the bone marrow. All participants had received at least one prior line of treatment.
Pfizer said Wednesday that the study met its primary endpoint, and that the drug's safety profile was consistent with prior results.
Chief Oncology Officer Jeff Legos said the data reinforces Pfizer's confidence in Elrexfio's potential to benefit patients earlier in their treatment journey. The data also supports the company's strategy to evaluate the drug both as monotherapy and as part of combination approaches across multiple lines of therapy, he added.
Overall survival data weren't mature at the time of the interim analysis, and the trial remains ongoing to assess that key secondary endpoint, the company said.
Elrexfio is already approved in the U.S. for heavily pretreated patients, and Pfizer is seeking to expand its use into earlier lines of therapy.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
04-29-26 0809ET
